RIDDLE&CODE
13.4.2021 10:17:12 CEST | Business Wire | Press release
RIDDLE&CODE FinTech Solutions, an innovative European company that empowers financial institutions to handle all aspects of digital asset management, announced today that LiteBit, the leading Dutch cryptocurrency exchange, has chosen its Token Management Platform (TMP) to scale infrastructure, respond to regulatory requirements and provide advanced capabilities to its growing customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005034/en/
Over the last few years, the European Union has significantly tightened its regulations on crypto service providers, including the recently updated 5th Anti-Money Laundering Directive (AMLD5). The newly implemented AMLD5 guidelines oblige service providers such as crypto exchanges and custodians to adhere to the same regulatory provisions as traditional financial institutions.
“The Dutch implementation of the regulations currently goes beyond EU guidelines and calls for extensive identification of customers and monitoring of transactions as well as extensive reporting and audit capabilities,” said Berit Fuss, Director of FinTech Solutions at RIDDLE&CODE. “These requirements have turned out to be quite burdensome and have forced several crypto-related businesses to close or leave the Netherlands.”
“Crypto exchanges across the industry are prioritising compliance with regulatory obligations. LiteBit is no exception,” said Arthur Van Lier, LiteBit’s COO. “The partnership with RIDDLE&CODE and the use of the cutting-edge TMP enables us to be compliant with both current and future regulations. But regulatory frameworks aren’t the only ones evolving,” he added. “At the moment, Decentralised Finance (DeFi) is one of the fastest-growing sectors in the crypto industry. However, due to the complexity of the applications and the efforts required to support several token protocols, many market players struggle to innovate and accommodate the integration of DeFi capabilities. With the TMP, we can benefit from these new business models and scale our operational capabilities.”
The TMP provides the Dutch exchange with a robust and transparent foundation for:
- Responding to the most pressing demands in an ever-changing regulatory environment, including AML/CFT requirements, customer due diligence, Know-Your-Customer (KYC) procedures and more.
- Scaling its operations by creating unlimited segregated accounts for its customers and automating certain processes to reduce the burden on the operational teams.
- Being flexible enough to offer DeFi services such as staking or voting on popular networks like Polkadot and Ethereum.
The Token Management Platform is the next generation of RIDDLE&CODE’s institutional-grade digital asset management solution. The cloud-based platform manages all aspects of key generation, custody, AML, regulatory compliance and token management. Accepted by the Swiss financial market authorities, the TMP is fully auditable and compliant with financial regulations, allowing clients to fulfill all transparency requirements in line with financial regulations and internal compliance policies.
“We are thrilled to work with LiteBit, our first crypto exchange customer,” said Alexander Koppel, CEO of RIDDLE&CODE. “This strategic partnership allows us to enter the Dutch market and help LiteBit in its journey to full regulatory compliance and expansion across Europe.”
RIDDLE&CODE FinTech Solutions
RIDDLE&CODE FinTech solutions, a subsidiary firm of the leading European blockchain interface company RIDDLE&CODE, builds hardware and software stacks that empower funds, crypto exchanges and regulated financial institutions to manage all aspects of key generation, custody, AML, regulatory compliance and token management with unmatched versatility and security.
LiteBit
LiteBit is a platform that makes trading in crypto safe, simple and personal. Its aim is to be the most customer-friendly and reliable platform in Europe. LiteBit supports investors in buying, selling and managing crypto, such as Bitcoin, Ethereum and more than 50 other types of coins.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom